OK 99
Alternative Names: Allogenic stem cell therapy - Celavie Biosciences; hNPCs - Celavie Biosciences; Human neural progenitor cell - Celavie Biosciences; OK99; OK99 undifferentiated stem cellsLatest Information Update: 28 Nov 2023
At a glance
- Originator Celavie Biosciences
- Developer California State University; Celavie Biosciences
- Class Antiepileptic drugs; Antiparkinsonians; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ataxia; Epilepsy; Parkinson's disease
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Epilepsy in USA (Parenteral)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Parkinson's-disease in Mexico (Intracerebral, Injection)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Ataxia in USA (Intra-arterial, Injection)